title: Treatment of Ph'-positive chronic myelogenous leukemia (CML) with recombinant interferon alfa-2b (Intron A).
authors.affiliation: Department of Human Biopathology, University La Sapienza, Rome, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Alimena
authors.forename: E
authors.initials: E
authors.lastname: Morra
authors.forename: M
authors.initials: M
authors.lastname: Lazzarino
authors.forename: A M
authors.initials: AM
authors.lastname: Liberati
authors.forename: E
authors.initials: E
authors.lastname: Montefusco
authors.forename: D
authors.initials: D
authors.lastname: Inveradi
authors.forename: P
authors.initials: P
authors.lastname: Bernasconi
authors.forename: M
authors.initials: M
authors.lastname: Mancini
authors.forename: F
authors.initials: F
authors.lastname: Grignani
authors.forename: C
authors.initials: C
authors.lastname: Bernasconi
mesh_terms: D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D011897:Random Allocation; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins